Dalriada brings in former Evotec executive Adam Davenport to lead strategy execution as Chief R&D Officer

TORONTO, May 03, 2023 (GLOBE NEWSWIRE) -- Dalriada, a leading Canadian contract research organization specializing in small molecule therapies, announces today that it has strengthened its executive leadership team, appointing Adam Davenport, Ph.D. as its Chief Research & Development Officer (CRDO).

Dr. Davenport joins from Evotec and will assume strategic and scientific execution responsibility for all of Dalriada’s programs, as well as its current and future R&D capabilities.

Serving most recently as Head of Global Molecular Discovery at Evotec where he spent his whole career, Dr. Davenport is a seasoned drug discovery leader and innovator who brings over 22 years of hands-on life science and partnership organization experience, having contributed to drug candidates and clinical assets through both governance and scientific leadership roles.

Dr. Davenport has a strong track record of progressing multiple projects through Discovery into Clinical evaluation and is lead inventor of P2X3R antagonists Eliapixant and Filopixant, achieving Phase 2a PoCs in Persistent Chronic Cough (PCC), and Bradykinin B1R antagonist Fulimetibant, undergoing a Phase 2a study to treat diabetic neuropathic pain (DNP).

His expertise spans across modalities, diverse target classes (GPCRs, ion-channels, PPIs, CNS, kinases, enzymes) and therapeutic areas (pain, inflammation, cognition, metabolic, Women’s Health, and respiratory).

I am thrilled to welcome Dr. Davenport to Dalriada as its new CRDO,” said Dr. Diana Kraskouskaya, Dalriada’s CEO and co-founder. Throughout his outstanding career at Evotec, Dr. Davenport has been at the forefront of drug discovery. He is a renowned chemist and authority in his area of expertise, and we believe his addition to the team will further strengthen our strategies and capabilities, as we strive to become the partner of choice for our biotech partners and clients,” she added.

Dalriada’s co-founder & CSO Prof. Patrick Gunning added: “At Dalriada we look forward to leveraging Dr. Davenport’s vast experience and insights gained from over 20 years spent at Evotec, and we are excited that our team and clients will benefit from his expertise in a wide range of modalities and disease areas.

Dr. Davenport commented on his appointment: “I am delighted to join Dalriada, a company purposely built as an agile, co-located, and integrated drug discovery partner, which pioneers its unique TURN-KEYTM model to accelerate the discovery and development journey of high value small molecule therapeutics from concept to IND.”

“The company is at the forefront of covalent and other novel small molecule modality drug discovery and combining this with its TURN-KEYTM operational model, provides the flexibility, creativity, and innovation that the biotech and VC sectors need to drive value creation and return on investment.”

As a veteran of the CRO world, I have been hugely impressed by the passion, knowledge, drive, and entrepreneurial spirit of Dalriada’s leadership team. I look forward to working alongside them to collectively make a difference for patients, by strategically leading the Company’s R&D.”

Dr. Davenport will be based out of Dalriada’s UK site, as part of the Company’s growing presence in Europe, focusing on project strategy and leadership.

A detailed biography for Dr. Davenport is available at www.dalriadatx.com/about/adam-davenport/

About Dalriada Drug Discovery Inc.

Dalriada, through its TURN-KEY™ Drug Discovery services model, provides a full suite of drug discovery, medicinal chemistry and intellectual property services for semi-virtual, lean biotechnology clients who focus on developing small molecule therapies. With R&D operations in Mississauga, Canada, Dalriada builds focused teams with expertise in MedChem, Biology and ADME to allow for the most rapid and cost-effective project execution and value building. Dalriada has niche expertise in several areas including covalent drug discovery, GPCR programs, targeted protein degradation, novel hetero-bifunctional modalities and CNS programs, with proprietary screening platforms in several of these areas.

About Dalriada’s TURN-KEY model

TURN-KEYTM provides a powerful one-stop alternative to the prevailing CRO models, fulfilling the most common needs of small to medium-size biotech companies. Via its three key operational pillars of Discovery Labs, Discovery Strategy and Discovery Management, the model reduces the costs of internal R&D and G&A, shortens the timelines to reaching value inflection points, and removes the burden of managing a network of sub-contractors. Our partners instantaneously tap into deep expertise in small molecule discovery (including a curated network of global Key Opinion Leaders), agile execution in integrated lab, and subcontracting and project management teams. The model is fundamentally based on agility, collaborative approach, focus on building value, expert input, and quality execution.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0dc99ed0-3885-4f79-9b33-12e7d9c075ae

For further information, please contact: Dr. Diana Kraskouskaya CEO diana@dalriadatx.com www.dalriadatx.com

Primary Logo

Dr. Adam Davenport joins Dalriada Drug Discovery as Chief R&D Officer
Dr. Adam Davenport joins Dalriada Drug Discovery as Chief R&D Officer

Back to news